Literature DB >> 11595773

Developmental and regional distribution of aspartoacylase in rat brain tissue.

K K Bhakoo1, T J Craig, P Styles.   

Abstract

The function of N-acetyl-aspartate (NAA), a predominant molecule in the brain, has not yet been determined. However, NAA is commonly used as a putative marker of viable neurones. To investigate the possible function of NAA, we determined the anatomical, developmental and cellular distribution of aspartoacylase, which catalyses the hydrolysis of NAA. Levels of aspartoacylase activity were measured during postnatal development in several brain regions. The differential distribution of aspartoacylase activity in purified populations of cells derived from the rat CNS was also investigated. The developmental and anatomical distribution of aspartoacylase correlated with the maturation of white matter tracts in the rat brain. Activity increased markedly after 7 days and coincided with the time course for the onset of myelination in the rat brain. Gray matter showed little activity or developmental trend. There was a 60-fold excess in optic nerve (a white matter tract) when compared with cortex at 21 days of development. In the adult brain there was a 18-fold difference in corpus callosum compared with cortex (stripped of corpus callosum). Cellular studies demonstrated that purified cortical neurons and cerebellar granular neurones have no activity. Primary O-2A progenitor cells had moderate activity, with three-fold higher activity in immature oligodendrocyte and 13-fold increase in mature oligodendrocytes (myelinating cells of the CNS). The highest activity was seen in type-2 astrocytes (20-fold difference compared with O-2A progenitors) derived from the same source. Aspartoacylase activity increased with time in freshly isolated astrocytes, with significantly higher activity after 15 days in culture. We conclude that aspartoacylase activity in the developing postnatal brain corresponds with maturation of myelination, and that the cellular distribution is limited to glial cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595773     DOI: 10.1046/j.1471-4159.2001.00561.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

Review 1.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

2.  Short-term cuprizone feeding verifies N-acetylaspartate quantification as a marker of neurodegeneration.

Authors:  Barbara Maria Krauspe; Wolfgang Dreher; Cordian Beyer; Werner Baumgartner; Bernd Denecke; Katharina Janssen; Claus-Dieter Langhans; Tim Clarner; Markus Kipp
Journal:  J Mol Neurosci       Date:  2014-09-05       Impact factor: 3.444

3.  Aspartoacylase supports oxidative energy metabolism during myelination.

Authors:  Jeremy S Francis; Louise Strande; Vladamir Markov; Paola Leone
Journal:  J Cereb Blood Flow Metab       Date:  2012-05-23       Impact factor: 6.200

4.  Metabolic characteristics of cortical malformations causing epilepsy.

Authors:  S G Mueller; K D Laxer; J A Barakos; N Cashdollar; D L Flenniken; P Vermathen; G B Matson; M W Weiner
Journal:  J Neurol       Date:  2005-04-29       Impact factor: 4.849

Review 5.  N-acetylaspartate in the vertebrate brain: metabolism and function.

Authors:  Morris H Baslow
Journal:  Neurochem Res       Date:  2003-06       Impact factor: 3.996

6.  Making the White Matter Matters: Progress in Understanding Canavan's Disease and Therapeutic Interventions Through Eight Decades.

Authors:  Seemin S Ahmed; Guangping Gao
Journal:  JIMD Rep       Date:  2015-01-21

7.  Transcriptional regulation of N-acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron-glia communication during energetic crisis.

Authors:  Samantha Zaroff; Paola Leone; Vladimir Markov; Jeremy S Francis
Journal:  Mol Cell Neurosci       Date:  2015-03-10       Impact factor: 4.314

8.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

9.  Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.

Authors:  Maria Traka; Robert L Wollmann; Sonia R Cerda; Jason Dugas; Ben A Barres; Brian Popko
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

10.  Reduced extrahippocampal NAA in mesial temporal lobe epilepsy.

Authors:  Susanne G Mueller; Joyce Suhy; Kenneth D Laxer; Derek L Flenniken; Jana Axelrad; Andres A Capizzano; Michael W Weiner
Journal:  Epilepsia       Date:  2002-10       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.